Effectiveness of an ACT-Based Cognitive Intervention on Quality of Life and Cognitive Function in Elderly Residents With MCI

NCT06753578 · tracked via the Priya Life Science Spain tracker

Sponsor

Instituto de Investigación Marqués de Valdecilla

Phase

Not applicable

Started

2024-01-01

Last updated

2024-12-31

Condition(s) studied

Mild Cognitive Impairment

Investigational drug(s) / intervention(s)

Acceptance and Commitment Therapy (ACT)standard care

Acceptance and Commitment Therapy (ACT): Acceptance and Commitment Therapy (ACT); Quality of Life (QOL); Mild Cognitive Impairment (MCI); cognitive function; elderly; psychological flexibility.

standard care: standard care

Study summary

This study investigates the effects of an Acceptance and Commitment Therapy (ACT)-based cognitive intervention on Quality of Life (QOL) and cognitive function among elderly residents with Mild Cognitive Impairment (MCI) in long-term care settings. The study assesses immediate and long-term impacts on cognitive function, psychological flexibility, social engagement, and overall well-being through structured ACT-based training.

Eligibility

Sex

ALL

Min age

65 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Residents aged 65 and older diagnosed with MCI, able to provide informed consent, and residing in participating long-term care facilities. Exclusion Criteria: * Individuals with severe cognitive impairment, unstable medical conditions, or psychiatric diagnoses that would interfere with participation.

Primary outcome measure(s)

Change in Quality of Life as measured by the QOL-AD scale — Baseline, post-intervention (12 weeks), and 6-month follow-up
Quality of Life will be assessed using the QOL-AD scale, a validated questionnaire for evaluating the quality of life in individuals with cognitive impairment. Changes in mean scores from baseline to each time point will be reported
Change in cognitive function as measured by the Mini-Mental State Examination (MMSE) — Baseline, post-intervention (12 weeks), and 6-month follow-up
Cognitive function will be evaluated using the MMSE, a widely used tool for cognitive assessment. Mean changes in scores from baseline to each time point will be analysed and reported

Trial sites (1)

Facility	City	Region	Status
Religious congregation	Santander	Cantabria	Recruiting

More Instituto de Investigación Marqués de Valdecilla trials in Spain

Mepolizumab and in Office-office Nasal Polypectomy in Patients With Chronic Rhinosinusitis (CRS). Recruiting

Randomized a Clinical Trial With Medical Device in Acute Ischemic Stroke Starting soon

Utility of ROTEM® for Risk Stratification of Post-Invasive Procedure Hemorrhage in Patients With Cirrhosis (CIR-ROTEM) Recruiting

OROPHARYNGEAL MYOFUNCTIONAL THERAPY IN OBSTRUCTIVE SLEEP APNEA Recruiting

Prophylaxis of Cytomegalovirus Infection With Adoptive Cell Inmunotherapy Recruiting

Other trials for the same condition

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI) Active, not recruiting

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants Active, not recruiting

HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population Recruiting

Longitudinal Early-onset Alzheimer's Disease Study Protocol Active, not recruiting

Evaluation of the Effects of a Nutritional Intervention of Ketogenic Medium-chain Triglycerides and B-vitamins on Cognitive Functioning in Older Adults With Mild Cognitive Impairment (COGNIKET-MCI) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06753578 on ClinicalTrials.gov ↗ ← All trials in Spain